高级检索
当前位置: 首页 > 详情页

Network pharmacology-based dissection of the underlying mechanisms of dyspnoea induced by zedoary turmeric oil

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. [2]Beijing Key Laboratory for Evaluation of Rational Drug Use, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. [3]School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
出处:
ISSN:

关键词: binding affinity dyspnoea haemoglobin network pharmacology zedoary turmeric oil

摘要:
Zedoary turmeric oil (ZTO) has been widely used in clinic. However, the unpleasant induced dyspnoea inevitably impedes its clinical application. Thus, it is urgent to elucidate the mechanism underlying the ZTO-induced dyspnoea. In this study, network pharmacology was firstly performed to search the clue of ZTO-induced dyspnoea. The key target genes of ZTO-induced dyspnoea were analysed using GO enrichment analysis and KEGG pathway analysis. GO analysis suggested that haem binding could be a key molecular function involved in ZTO-induced dyspnoea. Hence, the haemoglobin (Hb) was focused for its oxygen-carrying capacity with haem as its critical component binding to the oxygen. Ultraviolet-visible absorption spectrum indicated that the ZTO injection (ZTOI) perturbed the Soret band of Hb, suggesting an interaction between ZTO and Hb. GC-MS analysis revealed that beta-elemene, germacrone, curdione and furanodiene were main components of ZTOI. Molecular docking was used to illustrate the high affinity between representative sesquiterpenes and Hb, which was finally confirmed by surface plasmon resonance, suggesting their potential roles in dyspnoea by ZTO. Following a network pharmacology-driven strategy, our study revealed an intervened Hb-based mechanism underlying the ZTO-induced dyspnoea, providing a reference for elucidating mechanism underlying adverse drug reactions of herbal medicines in clinic.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 药学 3 区 毒理学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 毒理学 4 区 药学
JCR分区:
出版当年[2020]版:
Q2 TOXICOLOGY Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q2 PHARMACOLOGY & PHARMACY Q3 TOXICOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2020版] 出版当年五年平均[2016-2020] 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. [2]Beijing Key Laboratory for Evaluation of Rational Drug Use, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
通讯作者:
通讯机构: [1]Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. [2]Beijing Key Laboratory for Evaluation of Rational Drug Use, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. [3]School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China. [*1]School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China [*2]Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)